1. Home
  2. GKOS vs ALK Comparison

GKOS vs ALK Comparison

Compare GKOS & ALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • ALK
  • Stock Information
  • Founded
  • GKOS 1998
  • ALK 1932
  • Country
  • GKOS United States
  • ALK United States
  • Employees
  • GKOS N/A
  • ALK N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • ALK Air Freight/Delivery Services
  • Sector
  • GKOS Health Care
  • ALK Consumer Discretionary
  • Exchange
  • GKOS Nasdaq
  • ALK Nasdaq
  • Market Cap
  • GKOS 5.1B
  • ALK 6.0B
  • IPO Year
  • GKOS 2015
  • ALK N/A
  • Fundamental
  • Price
  • GKOS $94.31
  • ALK $50.92
  • Analyst Decision
  • GKOS Strong Buy
  • ALK Strong Buy
  • Analyst Count
  • GKOS 13
  • ALK 11
  • Target Price
  • GKOS $135.15
  • ALK $66.73
  • AVG Volume (30 Days)
  • GKOS 914.5K
  • ALK 3.1M
  • Earning Date
  • GKOS 04-30-2025
  • ALK 07-16-2025
  • Dividend Yield
  • GKOS N/A
  • ALK N/A
  • EPS Growth
  • GKOS N/A
  • ALK 48.41
  • EPS
  • GKOS N/A
  • ALK 2.83
  • Revenue
  • GKOS $404,523,000.00
  • ALK $12,640,000,000.00
  • Revenue This Year
  • GKOS $27.89
  • ALK $22.86
  • Revenue Next Year
  • GKOS $27.57
  • ALK $6.91
  • P/E Ratio
  • GKOS N/A
  • ALK $17.99
  • Revenue Growth
  • GKOS 23.92
  • ALK 20.82
  • 52 Week Low
  • GKOS $77.10
  • ALK $32.62
  • 52 Week High
  • GKOS $163.71
  • ALK $78.08
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 50.08
  • ALK 50.68
  • Support Level
  • GKOS $93.52
  • ALK $51.17
  • Resistance Level
  • GKOS $101.57
  • ALK $53.12
  • Average True Range (ATR)
  • GKOS 3.33
  • ALK 1.69
  • MACD
  • GKOS 0.40
  • ALK -0.11
  • Stochastic Oscillator
  • GKOS 42.24
  • ALK 32.90

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About ALK Alaska Air Group Inc.

Alaska Air Group Inc operates two airlines, Alaska and Horizon in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico, and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements (CPA). The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary and Mileage Plan passenger revenue.

Share on Social Networks: